Director of the National Research Center for Epidemiology and Microbiology named after N.F. Gamalei Alexander Gunzburg spoke about the timing of mass vaccination of Russian citizens against coronavirus. According to Channel One, the process will take at least six months.
“We hope that mass vaccination will begin in early autumn.We will assume in the best case scenario that it will take six months – seven – eight – nine months, yes, the vaccination process and its scaling, ”the scientist said. According to him, to instill the entire population of the country immediately will not work.
Gunzburg had previously injected himself with the coronavirus vaccine, created at the SRC them. Gamalei. He noted that the production of the drug with the vaccine is scheduled to begin in August.
Over the past day, 8.9 thousand cases of a new type of coronavirus were detected in Russia, while 5.5 thousand patients fully recovered. Less than a third of new cases occur in Moscow – Moscow and St. Petersburg retain their positions in the top three in terms of growth. In total, 353.4 thousand cases of COVID-19 were recorded in the Russian Federation.
Now, according to Gunzburg, specialists are completing preclinical trials of the rodent vaccine. The development of the drug is proceeding according to the plan approved by the Ministry of Health of Russia.
“We checked the possible toxicity. The result is positive. We are also completing a study on monkeys – it confirmed the high immunogenicity and safety of the drug, ”said Gunzburg. He also noted that with a positive result of preclinical trials, scientists in June will turn to the Ministry of Health with a request to test the vaccine on volunteers.
On May 22, it became known that scientists from the Research Center named after N.F. Gamalei tested the genetically engineered vaccine for coronavirus they developed on themselves.
“Everyone is alive, healthy and happy,” said the Director of Gunzburg. He noted that the developers are not so much testing the vaccine on themselves as protecting themselves to work on the drug in the context of the coronavirus pandemic.
The drug is being developed by genetic engineering, and officially it is in preclinical trials. Gunzburg explained that the vector vaccine NITsEM them. Gamalei is developing on the basis of adenovirus DNA into which a new type of coronavirus gene is inserted.
The “old” adenovirus is used as a container for delivering the coronavirus gene to cells and launching protein synthesis there – the “corona”, in honor of which the virus got its name. it
it is required in order for the human immune system to “get to know” a potential adversary.
In May, Russian Minister of Health Mikhail Murashko announced that they plan to start clinical trials of the coronavirus vaccine in a month. “Vaccines for the immunization of the disease are being intensively worked on, a clinical trial is planned to begin in a month,” said the Russian Minister of Health. Murashko also reported that the first Russian preparations for vaccination against coronavirus will appear in late July.
May 7, Italian scientists announced the creation of the “first in the world” vaccine that can defeat the coronavirus. The vaccine was developed by Takis Biotech. In early March, she announced the start of development, and then received permission from the Italian Ministry of Health for preclinical studies. The results themselves, however, have not yet been published; they are known only from the words of the company’s employees.
The vaccine is currently tested in mice. She was able to cause the production of antibodies necessary for the fight against coronavirus. “Human trials are expected after this summer,” said company CEO Luigi Auriziccio. “As far as we know, we were the first in the world to demonstrate the neutralization of coronavirus with a vaccine.”
Back in March, Professor Gunzburg, in an article for Gazeta.Ru, made recommendations for the prevention of coronavirus infection.
“As meansnon-specific (and safe for the body) drug prevention, it is rational to use drugs – interferon inducers registered in the Russian Federation, which means they have proven their safety, quality and effectiveness in various viral infections. Among these drugs include meglumine acridone acetate, tilorone, kagocel, sodium oxodihydroacridinyl acetate, sodium ribonucleate and others. For the most part, these are originally Russian and Soviet developments that are prescribed to be taken at the first symptoms of ARVI, ”the scientist wrote.
– .
